06/12/2007
TIPS nell’ascite refrattaria:una meta-analisi….
Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites: A Meta-analysis of Individual Patient Data. Salerno F, Cammà C, Enea M, Rössle M, Wong F. Gastroenterology. 2007 Jun 20; [Epub ahead of print]
03/12/2007
HCV genotipo1 b : rischio aumentato di HCC…
Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: A seventeen-year prospective cohort study.Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatology. 2007 Aug 6;
01/12/2007
Screening e outcome dell’atresia biliare
Screening and outcomes in biliary atresia: summary of a National Institutes of Health workshop. Sokol RJ, Shepherd RW, Superina R, Bezerra JA, Robuck P, Hoofnagle JH. Hepatology. 2007 Aug;46(2):566-81.
30/09/2007
L’atorvastatina non migliora la colestasi nei pazienti con PBC
Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid.Stojakovic T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Stadlbauer V, Gurakuqi G, Stauber RE, März W, Trauner M. Hepatology. 2007 Aug 1;
26/09/2007
EPATITE C, FORTE LEGAME CON IL DIABETE DI TIPO 2
Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Huang JF, Dai CY, Hwang SJ, Ho CK, Hsiao PJ, Hsieh MY, Lee LP, Lin ZY, Chen SC, Hsieh MY, Wang LY, Shin SJ, Chang WY, Chuang WL, Yu ML.Am J Gastroenterol. 2007 Jun;102(6):1237-43.
18/09/2007
Le infezioni condizionanno morbidità e mortalità nella cirrosi
Bacterial infection-related morbidity and mortality in cirrhosis.Christou L, Pappas G, Falagas ME. Am J Gastroenterol. 2007 Jul;102(7):1510-7.
16/09/2007
Review sul trattamento dell'epatite B
The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Lai CL, Yuen MF.Ann Intern Med. 2007 Jul 3;147(1):58-61.
14/09/2007
Overlap di PBC e epatite autoimmune
Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes.Silveira MG, Talwalkar JA, Angulo P, Lindor KD.Am J Gastroenterol. 2007 Jun;102(6):1244-50.
08/09/2007
Non tutti i pazienti HCV+ genotipo 2-3 si beneficiano della short therapy
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S; ACCELERATE Investigators. N Engl J Med. 2007 Jul 12;357(2):124-34.
06/09/2007
Outcomes clinicamente rilevanti nella valutazione della sindrome epatorenale
Systematic review: renal and other clinically relevant outcomes in hepatorenal syndrome trials. Tandon P, Bain VG, Tsuyuki RT, Klarenbach S.Aliment Pharmacol Ther. 2007 May 1;25(9):1017-28.
02/09/2007
Trattamento dell’epatite C dopo il trapianto
Review article: the treatment of hepatitis C virus recurrence after liver transplantation.Arjal RR, Burton JR, Villamil F, Rosen HR. Aliment Pharmacol Ther. 2007 Jul 15;26(2):127-40.
20/08/2007
Differenze nell’accesso al trapianto epatico........
Differences in access to liver transplantation: disease severity, waiting time, and transplantation center volume. Ahmad J, Bryce CL, Cacciarelli T, Roberts MS. Ann Intern Med. 2007 May 15;146(10):707-13.
17/08/2007
Caffè e HCC una meta-analisi....
Coffee consumption and risk of liver cancer: a meta-analysis. Larsson SC, Wolk A.Gastroenterology. 2007 May;132(5):1740-5.
15/08/2007
Fibrosi epatica e NASH.....
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. Hepatology. 2007 Apr;45(4):846-54.
13/08/2007
Cirrosi HCV utile la terapia antivirale dopo il trapianto….
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Carrion JA, Navasa M, Garcia-Retortillo M, Garcia-Pagan JC, Crespo G, Bruguera M, Bosch J, Forns X.Gastroenterology. 2007 May;132(5):1746-56.
11/08/2007
Cirrosi da HBV: Lamivudina e Immunoglobuline post-trapianto
Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, McCaughan GW; Australasian Liver Transplant Study Group. Gastroenterology. 2007 Mar;132(3):931-7.
08/08/2007
Analisi morfometrica della fibrosi epatica…
Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis.Goodman ZD, Becker RL, Pockros PJ, Afdhal NH. Hepatology. 2007 Apr;45(4):886-94.
30/07/2007
Infezioni e mortalità nella cirrosi
Bacterial Infection-Related Morbidity and Mortality in Cirrhosis.Christou L, Pappas G, Falagas ME. Am J Gastroenterol. 2007 May 17; [Epub ahead of print]
24/07/2007
Epatite B e rischio cardiovascolare...
Hepatitis B virus seropositivity and the risk of stroke and myocardial infarction. Sung J, Song YM, Choi YH, Ebrahim S, Davey Smith G. Stroke. 2007 May;38(5):1436-41.
13/07/2007
La steatosi epatica aumenta il rischio di HCC
Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Pekow JR, Bhan AK, Zheng H, Chung RT. Cancer. 2007 May 8; [Epub ahead of print]
12/07/2007
Octreotide migliora l’ipertensione portale…
A 3-Month Course of Long-Acting Repeatable Octreotide (Sandostatin LAR) Improves Portal Hypertension in Patients With Cirrhosis: A Randomized Controlled Study. Spahr L, Giostra E, Frossard JL, Morard I, Mentha G, Hadengue A. Am J Gastroenterol. 2007 May 3; [Epub ahead of print]
07/07/2007
Epatite da HCV e rischio linfoma....
Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H, Engels EA.JAMA. 2007 May 9;297(18):2010-7.
03/07/2007
Fattori di rischio per mortalità post-operatoria in pazienti cirrotici
Risk factors for mortality after surgery in patients with cirrhosis. Teh SH, Nagorney DM, Stevens SR, Offord KP, Therneau TM, Plevak DJ, Talwalkar JA, Kim WR, Kamath PS.Gastroenterology. 2007 Apr;132(4):1261-9.
01/07/2007
TC per diagnosticare la steatosi epatica
Comparison of CT methods for determining the fat content of the liver.Kodama Y, Ng CS, Wu TT, Ayers GD, Curley SA, Abdalla EK, Vauthey JN, Charnsangavej C. AJR Am J Roentgenol. 2007 May;188(5):1307-12.
29/06/2007
Epatite B: adefovir aggiungerlo o sostituirlo alla lamivudina?
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ.Hepatology. 2007 Feb;45(2):307-13.
21/06/2007
Gli omega-3 riducono l’infiammazione epatica
Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines. Schmocker C, Weylandt KH, Kahlke L, Wang J, Lobeck H, Tiegs G, Berg T, Kang JX. Hepatology. 2007 Apr;45(4):864-9.
05/06/2007
Terapia del Barrett nel paziente cirrotico...
Endoscopic therapy in patients with Barrett's esophagus and portal hypertension. Prasad GA, Wang KK, Joyce AM, Kochman ML, Lutzke LS, Borkenhagen LS. Gastrointest Endosc. 2007 Mar;65(3):527-31.
04/06/2007
Noduli a contenuto lipidico nella cirrosi: diagnosi ed implicazioni cliniche
Fat-containing nodules in the cirrhotic liver: chemical shift MRI features and clinical implications.Yu JS, Chung JJ, Kim JH, Kim KW. AJR Am J Roentgenol. 2007 Apr;188(4):1009-16.
02/06/2007
MELD score di utilità limitata nell’epatite da acetaminofene
MELDscore as a predictor of liver failure and death in patients withacetaminophen-induced liver injury. Schmidt LE, Larsen FS. Hepatology. 2007 Mar;45(3):789-96.
31/05/2007
CELLULE STAMINALI MIDOLLO USATE PER RIGENERARE TESSUTO EPATICO
PortalVein Embolization and Autologous CD133+ Bone Marrow Stem Cells for LiverRegeneration: Initial Experience.Furst G, Schulte Am Esch J, Poll LW, Hosch SB,Fritz LB, Klein M, Godehardt E, Krieg A, Wecker B, Stoldt V, Stockschlader M,Eisenberger CF, Modder U, Knoefel WT. Radiology. 2007 Apr;243(1):171-9. Epub 2007 Feb 20.
22/05/2007
Inutile l’induzione con IFN in pz HCV+ con disordini della coagulazione
Inductionversus noninduction antiviral therapy for chronic hepatitis C virus in patientswith congenital coagulation disorders: a Canadian multicentre trial. ChatterjeeA, Swain MG, Lee SS, Bain VG, Peltekian K, Croitoru K, Adams PC, Kaita K,Teitel J, Heathcote EJ. Can J Gastroenterol. 2007Feb;21(2):91-5.
21/05/2007
Lattulosio utile nell’encefalopatia epatica minima
Lactuloseimproves cognitive functions and health-related quality of life in patientswith cirrhosis who have minimal hepatic encephalopathy. Prasad S, Dhiman RK,Duseja A, Chawla YK, Sharma A, Agarwal R. Hepatology. 2007 Mar;45(3):549-59.
19/05/2007
Cirrosi da HCV : la risposta all’IFN riduce la mortalità
Sustainedvirological response to interferon-alpha is associated with improved outcome inHCV-related cirrhosis: a retrospective study. Bruno S, Stroffolini T, ColomboM, Bollani S, Benvegnu L, Mazzella G, Ascione A, Santantonio T, Piccinino F,Andreone P, Mangia A, Gaeta GB, Persico M, Fagiuoli S, Almasio PL; ItalianAssociation of the Study of the Liver Disease (AISF). Hepatology. 2007 Mar;45(3):579-87.
15/05/2007
Epatite autoimmune: è la cirrosi a favorire la tossicità da AZA
Utilityof thiopurine methyltransferase genotyping and phenotyping, and measurement ofazathioprine metabolites in the management of patients with autoimmunehepatitis. HeneghanMA, Allan ML, Bornstein JD, Muir AJ, Tendler DA. JHepatol. 2006 Oct;45(4):584-91. Epub 2006 Jun 23.
11/05/2007
Trattamento della coinfezione da virus B e C nei pazienti HIV+
Treatmentof Chronic Hepatitis B or C in HIV-Infected Patients with Dual Viral Hepatitis.Soriano V, BarreiroP, Martin-Carbonero L, Castellares C, Ruiz-Sancho A, Labarga P, Ramos B,Gonzalez-Lahoz J. JInfect Dis. 2007 Apr 15;195(8):1181-3. Epub 2007Mar 2.
07/05/2007
FIBROSPECT II nella diagnosi della fibrosi epatica ….
Assessmentof FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients.Zaman A, Rosen HR, Ingram K, Corless CL, Oh E, Smith K.AmJ Med. 2007 Mar;120(3):280.e9-14.
29/04/2007
Il vaccino anti-HEV è efficace..
Safety and efficacy of a recombinant hepatitis E vaccine. Mrigendra Prasad Shrestha, Robert McNair Scott, Durga Man Joshi, Mammen P. Mammen, Gyan Bahadur Thapa, Narbada Thapa, Khin Saw Aye Myint, Marc Fourneau, Robert A. Kuschner, Sanjaya Kumar Shrestha, Marie Pierre David, Jitvimol Seriwatana, David W. Vaughn, Assad Safary, Timothy P. Endy, and Bruce L. Innis. N Engl J Med 2007 Mar 1; 356:895-903.
21/04/2007
ICT per la diagnosi dell’encefalopatia epatica
InhibitoryControl Test Is a Simple Method to Diagnose Minimal Hepatic Encephalopathy andPredict Development of Overt Hepatic Encephalopathy.Bajaj JS, Saeian K, VerberMD, Hischke D, Hoffmann RG, Franco J, Varma RR, Rao SM. Am J Gastroenterol.2007 Jan 11; [Epub ahead of print]
17/04/2007
Review sistematica su NASH e acidi biliari…
Bileacids for non-alcoholic fatty liver disease and/or steatohepatitis. Orlando R, Azzalini L, Orando S,Lirussi F. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005160.
12/04/2007
Fibroindex: un nuovo score predittivo di fibrosi
Fibroindex, a practical index forpredicting significant fibrosis in patients with chronic hepatitis C.Koda M,Matunaga Y, Kawakami M, Kishimoto Y, Suou T,Murawaki Y. Hepatology. 2007Jan 26;45(2):297-306
09/04/2007
Esperienza di 5 anni con adefovir nell’epatite cronica HBeAg-neg
Long-term therapywith adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5years.Hadziyannis SJ,Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, LimSG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL;Adefovir Dipivoxil 438 Study Group. Gastroenterology. 2006 Dec;131(6):1743-51.Epub 2006 Sep 20.
06/04/2007
Fibroscan e cirrosi HCV+: uno studio su un’ ampia coorte
Featuresassociated with success rate and performance of fibroscan measurements for thediagnosis of cirrhosis in HCV patients: A prospective study of 935 patients.KettanehA, Marcellin P, Douvin C, Poupon R, Ziol M, Beaugrand M, de Ledinghen V. JHepatol. 2006 Dec 12; [Epub ahead of print]
04/04/2007
Nuovo promettente farmaco per l’epatite da HCV
Rapid decline ofviral RNA in hepatitis C patients treated with VX-950: a phase Ib,placebo-controlled, randomized study.CHAR(13) + CHAR(10)Reesink HW, Zeuzem S, Weegink CJ,Forestier N, van Vliet A, van de Wetering de Rooij J, McNair L, Purdy S,Kauffman R, Alam J, Jansen PL. Gastroenterology.2006 Oct;131(4):997-1002.
30/03/2007
Hepatic fibrosis 2006: report della 3°AASLD Conference
Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference.Friedman SL, Rockey DC, Bissell DM.Hepatology. 2007 Jan;45(1):242-9.CHAR(13) + CHAR(10)
17/03/2007
Review sistematica sul trattamento con anabolizzanti nell’epatite alcolica
CHAR(13) + CHAR(10)Anabolic-androgenicsteroids for alcoholic liver disease. Rambaldi A, Gluud C. CochraneDatabase Syst Rev. 2006 Oct 18;(4):CD003045.
12/03/2007
Il fumo aumenta la severità della fibrosi epatica
Smoking andincreased severity of hepatic fibrosis in primary biliary cirrhosis: A crossvalidated retrospective assessment. Zein CO, Beatty K, Post AB, Logan L, Debanne S,McCullough AJ. Hepatology. 2006 Dec;44(6):1564-71.
11/03/2007
Review sistematica sul trattamento dell’ ascite refrattaria: TIPS o paracentesi?
TIPSversus paracentesis for cirrhotic patients with refractory ascites. Saab S,Nieto JM, Lewis SK, Runyon BA.CochraneDatabase Syst Rev. 2006 Oct 18;(4):CD004889.
09/03/2007
Nuovi anticorpi per la diagnosi di PBC
Antinuclearantibodies giving the 'multiple nuclear dots' or the 'rim-like/membranous'patterns: diagnostic accuracy for primary biliary cirrhosis.Granito A, MuratoriP, Muratori L, Pappas G, Cassani F, Worthington J, Guidi M, Ferri S, DE Molo C,Lenzi M, Chapman RW, Bianchi FB. AlimentPharmacol Ther. 2006 Dec;24(11-12):1575-83.
04/03/2007
Review sistematica sul trattamento dell’overdose di paracetamolo
Interventionsfor paracetamol (acetaminophen) overdose. Brok J, Buckley N, Gluud C. CochraneDatabase Syst Rev. 2006 Apr 19;(2):CD003328.
27/02/2007
Meta-analisi : valore diagnostico del fibrotest nell’epatite cronica.
Meta-analyses of Fibrotest diagnostic value in chronic liver disease. Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, de Ledinghen V. BMC Gastroenterol. 2007 Oct 15;7(1):40
24/02/2007
Adefovir nel trattamento dell’epatite cronica B
Long-termtherapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for upto 5 years. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G,Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K,Arterburn S, Chuck SL; Adefovir Dipivoxil 438 Study Group. Gastroenterology.2006 Dec;131(6):1743-51.
22/02/2007
L’uso terapeutico dell’acetaminofene causa insufficienza epatica?
Does therapeutic use of acetaminophen cause acute liver failure? Dart RC, Bailey E. Pharmacotherapy. 2007 Sep;27(9):1219-30.
20/02/2007
Review sistematica e analisi economica: sorveglianza dell’HCC
Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, Jackson S, Ryder S, Price A, Stein K. Health Technol Assess. 2007 Sep;11(34):1-206
16/02/2007
NASH: MEGLIO CIBI A BASSO INDICE GLICEMICO
Hepatic Steatosis and Increased Adiposity in Mice Consuming Rapidly vs. Slowly Absorbed Carbohydrate. Kelly B. Scribner, Dorota B. Pawlak and David S. Ludwig.Obesity 2007; 15:2190-2199
31/01/2007
Morbo di Wilson: sintomatologia, diagnosi e prognosi in un’ampia coorte
Clinical presentation, diagnosis and long-term outcome of Wilson's disease:a cohort study.U Merle, M Schaefer, P Ferenci, and W Stremmel.Gut 2007;56 115-120
30/01/2007
Pioglitazone migliora la NASH
A placebo-controlled trial of pioglitazone insubjects with nonalcoholic steatohepatitis. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B,Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, FinckeC, DeFronzo R, Bannayan GA, Schenker S, Cusi K. N Engl J Med. 2006 Nov30;355(22):2297-307.
28/01/2007
IFN per la prevenzione dell'HCC..
Prevention ofhepatocellular carcinoma recurrence with alpha-interferon after liver resectionin HCV cirrhosis.CHAR(13) + CHAR(10)Mazzaferro V, Romito R, Schiavo M, Mariani L, CameriniT, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M,Bonino F, Majno P, Llovet JM. Hepatology. 2006 Dec;44(6):1543-54.
27/01/2007
FEGATO: NUOVA TERAPIA POTREBBE EVITARE TRAPIANTO
Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure.Parekkadan B, van Poll D, Suganuma K, Carter EA, Berthiaume F, Tilles AW, Yarmush ML. PLoS ONE. 2007 Sep 26;2(9):e941.
26/01/2007
DIFFERENZE RAZZIALI EMERGONO NELLA GRAVITA' DELLA CBP
Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States.Peters MG, Di Bisceglie AM, Kowdley KV, Flye NL, Luketic VA, Munoz SJ, Garcia-Tsao G, Boyer TD, Lake JR, Bonacini M, Combes B; PUMPS Group. Hepatology. 2007 Sep;46(3):769-75
24/01/2007
NGF nuovo marker per le patologie epatiche
Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma.Rasi G, Serafino A, Bellis L, Lonardo MT, Andreola F, Zonfrillo M, Vennarecci G, Pierimarchi P, Vallebona PS, Ettorre GM, Santoro E, Puoti C. World J Gastroenterol. 2007 Oct 7;13(37):4986-95.
24/01/2007
NGF nuovo marker per le patologie epatiche
Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma.Rasi G, Serafino A, Bellis L, Lonardo MT, Andreola F, Zonfrillo M, Vennarecci G, Pierimarchi P, Vallebona PS, Ettorre GM, Santoro E, Puoti C. World J Gastroenterol. 2007 Oct 7;13(37):4986-95.
19/01/2007
Review sistematica sull’utilizzo di Ciclosporina vs Tacrolimus post-OLT
Cyclosporin versustacrolimus for liver transplanted patients. Haddad EM, McAlister VC, Renouf E, Malthaner R, KjaerMS, Gluud LL. Cochrane DatabaseSyst Rev. 2006 Oct 18;(4):CD005161.
16/01/2007
Spesso presenti epatociti dell’ospite nei fegati trapiantati….
Epithelialmicrochimerism: Consistent finding in human liver transplants. Gaia S, Cappia S, Smedile A,Bacillo E, Gaia E, Gubetta L, Rizzetto M.J Gastroenterol Hepatol. 2006Dec;21(12):1801-6.
15/01/2007
Epatite da HCV: attenzione all’EPO durante terapia con peg-IFN
Erythropoietintreatment is associated with more severe thrombocytopenia in patients withchronic hepatitis C undergoing antiviral therapy. Homoncik M, Sieghart W,Formann E, Schmid M, Ferenci P, Gangl A, Jilma B, Peck-Radosavljevic M. Am J Gastroenterol. 2006Oct;101(10):2275-82.
13/01/2007
Profilassi PBS riduce il rischio anche di HRS
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, Pardo A, Quintero E, Vargas V, Such J, Ginès P, Arroyo V. Gastroenterology. 2007 Sep;133(3):818-24.
13/01/2007
Profilassi PBS riduce il rischio anche di HRS
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, Pardo A, Quintero E, Vargas V, Such J, Ginès P, Arroyo V. Gastroenterology. 2007 Sep;133(3):818-24.
11/01/2007
Review sistematica sull’uso del Bicyclol nell’epatite B
Bicyclolfor chronic hepatitis B. Wu T, Roger H, Xie L, Liu G, Hao B. CochraneDatabase Syst Rev. 2006 Oct 18;(4):CD004480.
09/01/2007
Outcome long-term della terlipressina nell’HRS
Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.Testro AG, Wongseelashote S, Angus PW, Gow PJ. J Gastroenterol Hepatol. 2007 Sep 3;
09/01/2007
Outcome long-term della terlipressina nell’HRS
Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.Testro AG, Wongseelashote S, Angus PW, Gow PJ. J Gastroenterol Hepatol. 2007 Sep 3;
08/01/2007
Il TNM-6 è accurato nello staging dell’HCC
Prognosticvalue and clinical relevance of the 6th Edition 2002 American Joint Committeeon Cancer staging system in patients with resectable hepatocellular carcinoma.LeiHJ, Chau GY, Lui WY,Tsay SH, King KL, Loong CC, Wu CW.JAm Coll Surg. 2006 Oct;203(4):426-35. Epub 2006 Aug 23.
06/01/2007
Meta-analisi su UDCA e CBP
Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses.Gong Y, Huang Z, Christensen E, Gluud C. Am J Gastroenterol. 2007 Aug;102(8):1799-807.
06/01/2007
Meta-analisi su UDCA e CBP
Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses.Gong Y, Huang Z, Christensen E, Gluud C. Am J Gastroenterol. 2007 Aug;102(8):1799-807.
01/01/2007
E’ possibile la diagnosi non invasiva di varici esofagee?
Noninvasivediagnosis of esophageal varices: is it feasible?deFranchis R. Am J Gastroenterol. 2006 Nov;101(11):2520-2.